Evidence map›Paper›PMID 28378849›Full record

ArticleEuropean journal of clinical nutrition2017

Prediagnostic enterolactone concentrations and mortality among Danish men diagnosed with prostate cancer.

A K Eriksen, C Kyrø, N Nørskov, A K Bolvig, J Christensen, A Tjønneland, K Overvad, R Landberg, A Olsen

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Molecules (Basel, Switzerland) · 2019
    Article
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

A K EriksenUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
C KyrøUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
N NørskovDepartment of Animal Science, Aarhus University, Tjele, Denmark.
A K BolvigDepartment of Animal Science, Aarhus University, Tjele, Denmark.
J ChristensenUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
A TjønnelandUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
K OvervadDepartment of Public Health, Section for Epidemiology, Aarhus University, Aarhus C, Denmark.
R LandbergDepartment of Molecular Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden.
A OlsenUnit of Diet, Genes and Environment, Danish Cancer Society Research Center, Copenhagen, Denmark.
Danish Cancer Society · DKAarhus University · DKSwedish University of Agricultural Sciences · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

objectivesEvidence on the role of diet in relation to prostate cancer progression is sparse. Foods rich in lignans have shown beneficial effects on prostate cancer progression in both animal studies and small human intervention studies, including beneficial effects on prostate-specific antigen levels and tumour growth. The lignan metabolite, enterolactone, has further shown to slow prostate cancer cell growth in vitro. The aim was to investigate the association between prediagnostic enterolactone concentrations and mortality among men with prostate cancer.Subljects/Methods:Prediagnostic plasma concentrations of enterolactone from 1390 men diagnosed with prostate cancer from the Danish Diet, Cancer and Health cohort were related to all-cause or prostate cancer-specific death, using Cox proportional hazards models with follow-up time (from the date of diagnose until the date of death, emigration or end of follow-up by December 2013) as the underlying time axis.

resultsThe hazard ratios for enterolactone concentrations assessed linearly by 20 nmol/l increments was 0.95 (0.90, 1.02) for all-cause mortality and 0.98 (0.92, 1.05) for prostate cancer-specific mortality. Categorisation of enterolactone concentrations into quartiles did not reveal a different pattern. No effect modifications by smoking, body mass index or sport were observed, and the associations did not differ by prostate cancer aggressiveness.

conclusionsWe found no association between enterolactone concentrations and mortality among men diagnosed with prostate cancer.

Indexed as

DietEarly Detection of Cancer4-ButyrolactoneAdultCohort StudiesDenmarkHumansLignansMaleMiddle AgedProportional Hazards ModelsProstatic NeoplasmsRegistriesRisk FactorsSurvival AnalysisWhite People2,3-bis(3'-hydroxybenzyl)butyrolactone4-ButyrolactoneLignans

Identifiers

PMID28378849
OpenAlexW2604112927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.